David Vidal

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group.

Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group.

Journal: International journal of dermatology

Published: January 24, 2024

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 03, 2023

Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain.

Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain.

Journal: Actas dermo-sifiliograficas

Published: May 04, 2023

Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting.

Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting.

Journal: International journal of dermatology

Published: December 28, 2022

Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.

Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.

Journal: Dermatologic therapy

Published: August 23, 2022

Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group.

Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group.

Journal: Dermatologic therapy

Published: July 19, 2022

Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting.

Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting.

Journal: Dermatologic therapy

Published: May 17, 2022

Multicentric Study on High-Frequency Ultrasound Characterization of Calcium Deposits in Dermal and Subcutaneous Calciphylaxis and Calcinosis.

Multicentric Study on High-Frequency Ultrasound Characterization of Calcium Deposits in Dermal and Subcutaneous Calciphylaxis and Calcinosis.

Journal: Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine

Published: October 08, 2021

Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting.

Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting.

Journal: Journal of the American Academy of Dermatology

Published: October 08, 2021

High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting.

High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting.

Journal: International journal of dermatology

Published: September 14, 2021

Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.

Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.

Journal: Dermatologic therapy

Published: June 07, 2021

Apremilast improves quality of life and ultrasonography parameters in patients with nail psoriasis: A prospective cohort study.

Apremilast improves quality of life and ultrasonography parameters in patients with nail psoriasis: A prospective cohort study.

Journal: The Journal of dermatology

Published: May 14, 2021

Showing 1-12 of 39

Last Updated: 09/26/2026